Newronika plans to use the 13.6 million euros (about $14.3 million) raised in a funding round to support what could be a pivotal clinical trial of its adaptive deep brain stimulation (DBS) system, designed to adjust treatment in real time to better control the symptoms of Parkinson’s disease…
News
Wearable sensors that monitor motor symptoms like tremor can accurately assess eligibility of Parkinson’s disease patients for apomorphine pump therapy, aligning closely with traditional clinical evaluations, according to a study. The findings suggest that wearable sensors have “the potential to revolutionize the way patients are assessed and treated, ultimately…
A research initiative aims to create a mobile app using artificial intelligence (AI) to make strength training at home more effective for people with Parkinson’s disease and other neurological conditions. The technology is being developed by Myworkout AS, in collaboration with the Norwegian University of Science and Technology…
Supernus Pharmaceuticals is on track to make Onapgo (apomorphine hydrochloride) — its newly approved medication for treating motor fluctuations in advanced Parkinson’s disease — available to patients in the U.S. by summer. That’s according to Jonathan Rubin, MD, chief medical officer at Supernus, who said that, by…
People with chronic kidney disease, a condition characterized by a progressive loss of kidney function, have alpha-synuclein protein deposits in their kidneys, a study in China has found. Alpha-synuclein is a key marker of Parkinson’s disease, suggesting a possible link between kidney function and the neurodegenerative condition. “These findings are…
People with tremor-dominant Parkinson’s disease experience a higher burden of nonmotor symptoms than people with essential tremor (ET), according to a recent report. Overall nonmotor symptom severity, urinary symptoms, and loss of smell are among the factors that most clearly diverged between the two conditions. Researchers believe the…
Levels of the protein epidermal growth factor, or EGF, in blood may help predict the risk of cognitive decline in people with Parkinson’s disease, a study reports. The study, “Correlation between plasma epidermal growth factor and follow-up cognitive decline in Parkinson’s disease,” was published in Neurological…
A large proportion of people with Parkinson’s disease struggle with sleep problems, including issues with falling asleep or maintaining uninterrupted sleep, according to a large study out of Maynooth University in Ireland. Certain factors, such as being male or receiving a Parkinson’s diagnosis at a younger age, may…
Gardenin A, a compound found in a common South Asian shrub, lessened both cognitive and motor symptoms of Parkinson’s in a mouse model of the disease, according to a study. The compound reduced the loss of dopaminergic neurons — nerve cells that are gradually lost in Parkinson’s— and decreased…
An Australian company announced that it is working on a direct, nose-to-brain way of delivering dopamine that might more effectively treat Parkinson’s disease. PreveCeutical anticipates that this approach, based on what it calls a sol-gel solution that turns into a gel once in contact with mucosa tissue…
Recent Posts
- Parkinson’s trial targets inflammation before motor symptoms emerge
- My dad maintains an attitude of gratitude while living with Parkinson’s
- Motivation strategies may boost lung rehabilitation in Parkinson’s
- We saw a symptom of Parkinson’s. My uncle saw a missing jacket.
- New brain-mapping tool may improve DBS surgery for Parkinson’s